The novel calcium sensitiser, levosimendan (LS), and the β-adrenoceptor agonist dobutamine (DO), both improve cardiac haemodynamics in patients withsevere low-output heart failure (HF). However, co-administration of β-blockers may influence the action of these inotropic agents.

In a multicentre, randomised, double-blind trial in patients with severe low output HF (*n* = 203), the haemodynamic effects of LS and DO infusions over 24 hours were compared. The influence of concomitant β-blocker therapy (37% in the LS and 39% in the DO groups) were analysed separately. Patients were given either LS (loading dose of 24 μg/kg over 10 min followed by a continuous infusion of 0.1 μg/kg/min), or DO (continuous infusion of 5 μg/kg/min). The infusion rates were doubled if the cardiac index did not increase by ≥ 30% after 2 hours of treatment.

The use of β-blockers had significant effects on the increase in cardiac output and the decrease in pulmonary wedge pressure (*P* = 0.01 and *P* = 0.03, respectively) (Fig. [1](#F1){ref-type="fig"}). β-blockade attenuated the effect of DO but did not reduce the effects of LS. There was even a slight trend for improved haemodynamic benefits of LS in patients under β-blockade. These findings suggest that LS may be successfully combined with β-blockers to treat patients with low-output heart failure.
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Mean changes in cardiac output (CO) and pulmonary capillary wedge pressure (PCWP) in patients given LS (β- *n* = 69 and β+ *n* = 33) and DO (β- *n* = 67 and β+ *n* = 28).
